Cargando…
Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial
BACKGROUND: A previous randomised controlled trial (RCT) of patients with chronic low back pain (LBP) and vertebral bone marrow (Modic) changes (MCs) on magnetic resonance imaging (MRI), reported that a 3-month, high-dose course of antibiotics had a better effect than placebo at 12 months’ follow-up...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732434/ https://www.ncbi.nlm.nih.gov/pubmed/29246188 http://dx.doi.org/10.1186/s13063-017-2306-8 |
_version_ | 1783286696567111680 |
---|---|
author | Storheim, Kjersti Espeland, Ansgar Grøvle, Lars Skouen, Jan Sture Aßmus, Jörg Anke, Audny Froholdt, Anne Pedersen, Linda M. Haugen, Anne Julsrud Fors, Terese Schistad, Elina Lutro, Olav Marchand, Gunn Hege Kadar, Thomas Vetti, Nils Randen, Sigrun Nygaard, Øystein Petter Brox, Jens Ivar Grotle, Margreth Zwart, John-Anker |
author_facet | Storheim, Kjersti Espeland, Ansgar Grøvle, Lars Skouen, Jan Sture Aßmus, Jörg Anke, Audny Froholdt, Anne Pedersen, Linda M. Haugen, Anne Julsrud Fors, Terese Schistad, Elina Lutro, Olav Marchand, Gunn Hege Kadar, Thomas Vetti, Nils Randen, Sigrun Nygaard, Øystein Petter Brox, Jens Ivar Grotle, Margreth Zwart, John-Anker |
author_sort | Storheim, Kjersti |
collection | PubMed |
description | BACKGROUND: A previous randomised controlled trial (RCT) of patients with chronic low back pain (LBP) and vertebral bone marrow (Modic) changes (MCs) on magnetic resonance imaging (MRI), reported that a 3-month, high-dose course of antibiotics had a better effect than placebo at 12 months’ follow-up. The present study examines the effects of antibiotic treatment in chronic LBP patients with MCs at the level of a lumbar disc herniation, similar to the previous study. It also aims to assess the cost-effectiveness of the treatment, refine the MRI assessment of MCs, and further evaluate the impact of the treatment and the pathogenesis of MCs by studying genetic variability and the gene and protein expression of inflammatory biomarkers. METHODS/DESIGN: A double-blinded RCT is conducted at six hospitals in Norway, comparing orally administered amoxicillin 750 mg, or placebo three times a day, over a period of 100 days in patients with chronic LBP and type I or II MCs at the level of a MRI-confirmed lumbar disc herniation within the preceding 2 years. The inclusion will be stopped when at least 80 patients are included in each of the two MC type groups. In each MC type group, the study is designed to detect (β = 0.1, α = 0.05) a mean difference of 4 (standard deviation 5) in the Roland Morris Disability Questionnaire score between the two treatment groups (amoxicillin or placebo) at 1-year follow-up. The study includes cost-effectiveness measures. Blood samples are assessed for security measures and for possible inflammatory mediators and biomarkers at different time points. MCs are evaluated on MRI at baseline and after 12 months. A blinded intention-to-treat analysis of treatment effects will be performed in the total sample and in each MC type group. DISCUSSION: To ensure the appropriate use of antibiotic treatment, its effect in chronic LBP patients with MCs should be re-assessed. This study will investigate the effects and cost-effectiveness of amoxicillin in patients with chronic LBP and MCs at the level of a disc herniation. The study may also help to refine imaging and characterise the biomarkers of MCs. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02323412. Registered on 21 November 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2306-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5732434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57324342017-12-21 Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial Storheim, Kjersti Espeland, Ansgar Grøvle, Lars Skouen, Jan Sture Aßmus, Jörg Anke, Audny Froholdt, Anne Pedersen, Linda M. Haugen, Anne Julsrud Fors, Terese Schistad, Elina Lutro, Olav Marchand, Gunn Hege Kadar, Thomas Vetti, Nils Randen, Sigrun Nygaard, Øystein Petter Brox, Jens Ivar Grotle, Margreth Zwart, John-Anker Trials Study Protocol BACKGROUND: A previous randomised controlled trial (RCT) of patients with chronic low back pain (LBP) and vertebral bone marrow (Modic) changes (MCs) on magnetic resonance imaging (MRI), reported that a 3-month, high-dose course of antibiotics had a better effect than placebo at 12 months’ follow-up. The present study examines the effects of antibiotic treatment in chronic LBP patients with MCs at the level of a lumbar disc herniation, similar to the previous study. It also aims to assess the cost-effectiveness of the treatment, refine the MRI assessment of MCs, and further evaluate the impact of the treatment and the pathogenesis of MCs by studying genetic variability and the gene and protein expression of inflammatory biomarkers. METHODS/DESIGN: A double-blinded RCT is conducted at six hospitals in Norway, comparing orally administered amoxicillin 750 mg, or placebo three times a day, over a period of 100 days in patients with chronic LBP and type I or II MCs at the level of a MRI-confirmed lumbar disc herniation within the preceding 2 years. The inclusion will be stopped when at least 80 patients are included in each of the two MC type groups. In each MC type group, the study is designed to detect (β = 0.1, α = 0.05) a mean difference of 4 (standard deviation 5) in the Roland Morris Disability Questionnaire score between the two treatment groups (amoxicillin or placebo) at 1-year follow-up. The study includes cost-effectiveness measures. Blood samples are assessed for security measures and for possible inflammatory mediators and biomarkers at different time points. MCs are evaluated on MRI at baseline and after 12 months. A blinded intention-to-treat analysis of treatment effects will be performed in the total sample and in each MC type group. DISCUSSION: To ensure the appropriate use of antibiotic treatment, its effect in chronic LBP patients with MCs should be re-assessed. This study will investigate the effects and cost-effectiveness of amoxicillin in patients with chronic LBP and MCs at the level of a disc herniation. The study may also help to refine imaging and characterise the biomarkers of MCs. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02323412. Registered on 21 November 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2306-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-15 /pmc/articles/PMC5732434/ /pubmed/29246188 http://dx.doi.org/10.1186/s13063-017-2306-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Storheim, Kjersti Espeland, Ansgar Grøvle, Lars Skouen, Jan Sture Aßmus, Jörg Anke, Audny Froholdt, Anne Pedersen, Linda M. Haugen, Anne Julsrud Fors, Terese Schistad, Elina Lutro, Olav Marchand, Gunn Hege Kadar, Thomas Vetti, Nils Randen, Sigrun Nygaard, Øystein Petter Brox, Jens Ivar Grotle, Margreth Zwart, John-Anker Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title | Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title_full | Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title_fullStr | Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title_full_unstemmed | Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title_short | Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial |
title_sort | antibiotic treatment in patients with chronic low back pain and modic changes (the aim study): study protocol for a randomised controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732434/ https://www.ncbi.nlm.nih.gov/pubmed/29246188 http://dx.doi.org/10.1186/s13063-017-2306-8 |
work_keys_str_mv | AT storheimkjersti antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT espelandansgar antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT grøvlelars antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT skouenjansture antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT aßmusjorg antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT ankeaudny antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT froholdtanne antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT pedersenlindam antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT haugenannejulsrud antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT forsterese antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT schistadelina antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT lutroolav antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT marchandgunnhege antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT kadarthomas antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT vettinils antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT randensigrun antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT nygaardøysteinpetter antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT broxjensivar antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT grotlemargreth antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial AT zwartjohnanker antibiotictreatmentinpatientswithchroniclowbackpainandmodicchangestheaimstudystudyprotocolforarandomisedcontrolledtrial |